Revvity Inc - Company Profile
Powered by 
All the sales intelligence you need on Revvity Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Revvity Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Revvity Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Revvity Inc (Revvity), formerly Perkinelmer Inc, offers products, services, and solutions for the diagnostics, life sciences, and applied markets. The company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, and diagnosis. Revvity's major products include reagents, instruments, and software for life sciences and diagnostics applications. The company also offers cord blood and tissue banking, laboratory and research services. Its products find application in atomic spectroscopy, cell imaging and analysis, chromatography, analysis and detection, DNA/RNA isolation, in vivo imaging, molecular spectroscopy, protein analysis and detection, and tissue imaging, among others. The company operates in Asia, Europe, and Americas. Revvity is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
77 4th Avenue, Waltham, Massachusetts, 02451
Website
www.revvity.com
Telephone
1 781 6636900
No of Employees
11,000
Industry
Medical Equipment
Ticker Symbol & Exchange
RVTY (NYSE)
Revenue (2024)
$2.9B
3.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-10.8%
(2024 vs 2023)
Market Cap*
$12.4B
Net Profit Margin (2024)
XYZ
-13.9%
(2024 vs 2023)
* As of and is in US$
Revvity Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Consumables: | Research Services | Accell |
| Autosampler Supplies | OneSource Laboratory Services | AlphaPlex |
| Application Packs and Starter Kits | Genetic and Newborn Testing Services | AlphaLISA |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In May, the company secured approval from the US FDA for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). |
| 2026 | New Products/Services | In April, the company through its Revvity Signals Software business launched Signals BioDesign, a cloud-native molecular cloning solution. |
| 2026 | New Products/Services | In February, the company launched new discovery platforms and technologies to enhance drug discovery workflows. |
Competitor Comparison
| Key Parameters | Revvity Inc | Thermo Fisher Scientific Inc | Agilent Technologies Inc | Shimadzu Corp | Waters Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | United States of America |
| City | Waltham | Waltham | Santa Clara | Kyoto | Milford |
| State/Province | Massachusetts | Massachusetts | California | Kyoto | Massachusetts |
| No. of Employees | 11,000 | 125,000 | 17,900 | 14,481 | 7,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Prahlad R. Singh, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2019 | 60 |
| Maxwell Krakowiak | Chief Financial Officer; Senior Vice President | Senior Management | 2022 | 35 |
| Arvind Sundar-Rajan | Chief Digital Officer; Chief Strategy Officer; Senior Vice President | Senior Management | 2024 | - |
| Madhuri Hegde, Ph.D. | Chief Scientific Officer; Senior Vice President | Senior Management | 2023 | - |
| Miriame Victor | Chief Commercial Officer; Senior Vice President | Senior Management | 2021 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer